JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120614

Lovastatin (Mevinolin), HMG-CoA reductase inhibitor

Be the first to review this product! Submit a review

|

(7 Publications)

MW 404.5 Da, Purity >98%. Potent, competitive HMG-CoA reductase inhibitor (Ki = 0.6 nM). Blood-brain barrier permeable. Inhibits in vivo and in vitro cholesterol biosynthesis. Also reduces α-synuclein levels in vitro and in vivo.
2 Images
Functional Studies - Lovastatin (Mevinolin), HMG-CoA reductase inhibitor (AB120614)
  • FuncS

Unknown

Functional Studies - Lovastatin (Mevinolin), HMG-CoA reductase inhibitor (AB120614)

ab87359 staining cyclin A in DU145 cells treated with lovastatin (ab120614), by ICC/IF. Decrease in cyclin A expression correlates with increased concentration of lovastatin, as described in literature.
The cells were incubated at 37°C for 24h in media containing different concentrations of ab120614 (lovastatin) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab87359 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight® 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

Chemical Structure - Lovastatin (Mevinolin), HMG-CoA reductase inhibitor (AB120614)
  • Chemical Structure

Lab

Chemical Structure - Lovastatin (Mevinolin), HMG-CoA reductase inhibitor (AB120614)

2D chemical structure image of ab120614, Lovastatin (Mevinolin), HMG-CoA reductase inhibitor

Key facts

CAS number

75330-75-5

Purity

>98%

Form

Solid

form

Molecular weight

404.5 Da

Molecular formula

C<sub>2</sub><sub>4</sub>H<sub>3</sub><sub>6</sub>O<sub>5</sub>

PubChem

53232

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in ethanol to 50 mM

Biochemical name

Lovastatin

Biological description

Potent, competitive HMG-CoA reductase inhibitor (Ki = 0.6 nM). Blood-brain barrier permeable. Inhibits in vivo and in vitro cholesterol biosynthesis. Also reduces α-synuclein levels in vitro and in vivo.

Canonical smiles

CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C

Isomeric smiles

CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

InChi

InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1

InChiKey

PCZOHLXUXFIOCF-BXMDZJJMSA-N

IUPAC Name

[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate

style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column
style
left-column
style
left-column

Product protocols

style
left-column

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

International journal of biological sciences 20:2130-2148 PubMed38617541

2024

Dysregulated Ribosome Biogenesis Is a Targetable Vulnerability in Triple-Negative Breast Cancer: MRPS27 as a Key Mediator of the Stemness-inhibitory Effect of Lovastatin.

Applications

Unspecified application

Species

Unspecified reactive species

Chanjuan Zheng,Hui Yao,Lu Lu,Hongqi Li,Lei Zhou,Xueyan He,Xi Xu,Hongzhuo Xia,Siyu Ding,Yiyuan Yang,Xinyu Wang,Muyao Wu,Lian Xue,Sisi Chen,Xiaojun Peng,Zhongyi Cheng,Yian Wang,Guangchun He,Shujun Fu,Evan T Keller,Suling Liu,Yi-Zhou Jiang,Xiyun Deng

Cell reports 37:110056 PubMed34818551

2021

Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis.

Applications

Unspecified application

Species

Unspecified reactive species

Madeleine Dorsch,Manuela Kowalczyk,Mélanie Planque,Geronimo Heilmann,Sebastian Urban,Philip Dujardin,Jan Forster,Kristina Ueffing,Silke Nothdurft,Sebastian Oeck,Annika Paul,Sven T Liffers,Farnusch Kaschani,Markus Kaiser,Alexander Schramm,Jens T Siveke,Monte M Winslow,Sarah-Maria Fendt,Perihan Nalbant,Barbara M Grüner

Frontiers in oncology 11:656687 PubMed34150623

2021

Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.

Applications

Unspecified application

Species

Unspecified reactive species

Chanjuan Zheng,Shichao Yan,Lu Lu,Hui Yao,Guangchun He,Sisi Chen,Ying Li,Xiaojun Peng,Zhongyi Cheng,Mi Wu,Qiuting Zhang,Guifei Li,Shujun Fu,Xiyun Deng

Scientific reports 11:8743 PubMed33888740

2021

The antiviral effect of metformin on zika and dengue virus infection.

Applications

Unspecified application

Species

Unspecified reactive species

Carlos Noe Farfan-Morales,Carlos Daniel Cordero-Rivera,Juan Fidel Osuna-Ramos,Irma Eloisa Monroy-Muñoz,Luis Adrián De Jesús-González,José Esteban Muñoz-Medina,Arianna M Hurtado-Monzón,José Manuel Reyes-Ruiz,Rosa María Del Ángel

Molecular cell 75:252-266.e8 PubMed31202577

2019

Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.

Applications

Unspecified application

Species

Unspecified reactive species

Andres Canela,Yaakov Maman,Shar-Yin N Huang,Gordana Wutz,Wen Tang,Guido Zagnoli-Vieira,Elsa Callen,Nancy Wong,Amanda Day,Jan-Michael Peters,Keith W Caldecott,Yves Pommier,André Nussenzweig

Nature communications 8:1988 PubMed29215016

2017

low neurotrophin receptor CD271 regulates phenotype switching in melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Gaetana Restivo,Johanna Diener,Phil F Cheng,Gregor Kiowski,Mario Bonalli,Thomas Biedermann,Ernst Reichmann,Mitchell P Levesque,Reinhard Dummer,Lukas Sommer

Journal of Cancer 8:1655-1664 PubMed28775785

2017

Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yikun Peng,Guangchun He,Da Tang,Li Xiong,Yu Wen,Xiongying Miao,Zhangyong Hong,Hui Yao,Chao Chen,Shichao Yan,Lu Lu,Yingke Yang,Qinglong Li,Xiyun Deng
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB120651

Fluvastatin sodium salt, HMG-CoA reductase inhibitor

Chemical Structure - Fluvastatin sodium salt, HMG-CoA reductase inhibitor (AB120651)

  • 0
  • 0
Biochemicals

AB120488

Z-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor

Functional Studies - Z-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor (AB120488)

  • 0
  • 0
Biochemicals

AB120505

Simvastatin, HMG-CoA reductase inhibitor

Chemical Structure - Simvastatin, HMG-CoA reductase inhibitor (AB120505)

  • 0
  • 0
Primary Antibodies

AB15580

Anti-Ki67 antibody

BOND RX™ Validated|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Ki67 antibody (AB15580)

  • 5
  • 230

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com